Cargando…
A perspective to weaponize microRNAs against lung cancer
microRNAs are regulatory RNAs that silence specific mRNA by binding to it, inducing translational repression. Over the recent decades since the discovery of RNA interference, the field of microRNA therapeutics has expanded tremendously. The role of miRNAs in disease development has attracted researc...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
KeAi Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556932/ https://www.ncbi.nlm.nih.gov/pubmed/36262424 http://dx.doi.org/10.1016/j.ncrna.2022.09.009 |
_version_ | 1784807186381144064 |
---|---|
author | Murugan, Dhanashree Rangasamy, Loganathan |
author_facet | Murugan, Dhanashree Rangasamy, Loganathan |
author_sort | Murugan, Dhanashree |
collection | PubMed |
description | microRNAs are regulatory RNAs that silence specific mRNA by binding to it, inducing translational repression. Over the recent decades since the discovery of RNA interference, the field of microRNA therapeutics has expanded tremendously. The role of miRNAs in disease development has attracted researchers to investigate their potential in therapeutics. In lung cancer, multiple miRNAs are deregulated, and their involvement is observed in cell proliferation, immunomodulation, angiogenesis, and epithelial-mesenchymal transition. Thus, synthetic oligonucleotides are developed to downregulate the overexpressed miRNA or to upregulate the repressed miRNA. However, their clinical efficiency is limited due to the requirement for an effective delivery strategy. Advances in the current understanding of nanotechnology, biomaterial science, and disease molecular pathology have increased the chances of overcoming the limitations of miRNA-based therapy. This review enlists downregulated and upregulated miRNAs in lung cancer. This review also highlights the major contributions to miRNA-based therapeutics for lung cancer and strategies to overcome endosomal barriers. It also attempts to understand the nuances between current advancements in delivery methods, advantages, disadvantages, and practical issues for the large-scale development of miRNA-based therapeutics. |
format | Online Article Text |
id | pubmed-9556932 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | KeAi Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-95569322022-10-18 A perspective to weaponize microRNAs against lung cancer Murugan, Dhanashree Rangasamy, Loganathan Noncoding RNA Res Review Article microRNAs are regulatory RNAs that silence specific mRNA by binding to it, inducing translational repression. Over the recent decades since the discovery of RNA interference, the field of microRNA therapeutics has expanded tremendously. The role of miRNAs in disease development has attracted researchers to investigate their potential in therapeutics. In lung cancer, multiple miRNAs are deregulated, and their involvement is observed in cell proliferation, immunomodulation, angiogenesis, and epithelial-mesenchymal transition. Thus, synthetic oligonucleotides are developed to downregulate the overexpressed miRNA or to upregulate the repressed miRNA. However, their clinical efficiency is limited due to the requirement for an effective delivery strategy. Advances in the current understanding of nanotechnology, biomaterial science, and disease molecular pathology have increased the chances of overcoming the limitations of miRNA-based therapy. This review enlists downregulated and upregulated miRNAs in lung cancer. This review also highlights the major contributions to miRNA-based therapeutics for lung cancer and strategies to overcome endosomal barriers. It also attempts to understand the nuances between current advancements in delivery methods, advantages, disadvantages, and practical issues for the large-scale development of miRNA-based therapeutics. KeAi Publishing 2022-09-29 /pmc/articles/PMC9556932/ /pubmed/36262424 http://dx.doi.org/10.1016/j.ncrna.2022.09.009 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Article Murugan, Dhanashree Rangasamy, Loganathan A perspective to weaponize microRNAs against lung cancer |
title | A perspective to weaponize microRNAs against lung cancer |
title_full | A perspective to weaponize microRNAs against lung cancer |
title_fullStr | A perspective to weaponize microRNAs against lung cancer |
title_full_unstemmed | A perspective to weaponize microRNAs against lung cancer |
title_short | A perspective to weaponize microRNAs against lung cancer |
title_sort | perspective to weaponize micrornas against lung cancer |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556932/ https://www.ncbi.nlm.nih.gov/pubmed/36262424 http://dx.doi.org/10.1016/j.ncrna.2022.09.009 |
work_keys_str_mv | AT murugandhanashree aperspectivetoweaponizemicrornasagainstlungcancer AT rangasamyloganathan aperspectivetoweaponizemicrornasagainstlungcancer AT murugandhanashree perspectivetoweaponizemicrornasagainstlungcancer AT rangasamyloganathan perspectivetoweaponizemicrornasagainstlungcancer |